First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer
Author:
Funder
Eisai Co., Ltd
Publisher
Elsevier BV
Subject
General Medicine,Surgery
Reference35 articles.
1. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer;Baselga;N Engl J Med,2012
2. Lapatinib plus capecitabine for HER2-positive advanced breast cancer;Geyer;N Engl J Med,2006
3. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001
4. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer;Swain;N Engl J Med,2015
5. Trastuzumab emtansine for HER2-positive advanced breast cancer;Verma;N Engl J Med,2012
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A clinical systematic literature review of treatments among patients with advanced and/or metastatic human epidermal growth factor receptor 2 positive breast cancer;Journal of Comparative Effectiveness Research;2024-06
2. Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes;Cancer Medicine;2024-05
3. From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds;Frontiers in Pharmacology;2022-09-08
4. Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS);Cancer Science;2022-07-23
5. Prognostic importance of peripheral blood parameters in HER-2 positive metastatic breast cancer treated by pertuzumab, trastuzumab and docetaxel;Medical Science and Discovery;2021-12-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3